Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer: Recent developments in combination chemotherapy and radiotherapy

Richard J. Gralla, P. Harper, S. Johnson, F. M. Delgado

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine and cisplatin as one of the standard treatments for inoperable NSCLC. Alternative partners to cisplatin have been evaluated in combination therapy with vinorelbine with promising results emerging from combinations with carboplatin, ifosfamide, mitomycin C and gemcitabine. Three drug combinations such as vinorelbine, cisplatin and ifosfamide can clearly produce high response rates in patients with good performance status at the time of treatment. The ability of vinorelbine to contribute to disease reduction either alone or in combination with other cytotoxic drugs has made it possible to consider its use in neo-adjuvant therapy, while the synergistic action of vinorelbine with radiotherapy has encouraged the use of sequential or concomitant chemoradiotherapy producing high response rates after completion of both modalities. The possible role of post-operative adjuvant treatment with Vinorelbine either alone or in combination with cisplatin is being assessed in a prospective trial.

Original languageEnglish (US)
JournalAnnals of Oncology
Volume10
Issue numberSUPPL. 5
StatePublished - 1999
Externally publishedYes

Fingerprint

Combination Drug Therapy
Non-Small Cell Lung Carcinoma
Radiotherapy
Cisplatin
Ifosfamide
gemcitabine
Therapeutics
Carboplatin
Mitomycin
Chemoradiotherapy
Drug Combinations
vinorelbine
Pharmaceutical Preparations

Keywords

  • Cisplatin non-small-cell lung cancer
  • Neo- adjuvant
  • Radiotherapy
  • Vinorelbine

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer : Recent developments in combination chemotherapy and radiotherapy. / Gralla, Richard J.; Harper, P.; Johnson, S.; Delgado, F. M.

In: Annals of Oncology, Vol. 10, No. SUPPL. 5, 1999.

Research output: Contribution to journalArticle

@article{10e8b373910348fe82c5959ccc378d43,
title = "Vinorelbine (Navelbine{\circledR}) in the treatment of non-small-cell lung cancer: Recent developments in combination chemotherapy and radiotherapy",
abstract = "The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine and cisplatin as one of the standard treatments for inoperable NSCLC. Alternative partners to cisplatin have been evaluated in combination therapy with vinorelbine with promising results emerging from combinations with carboplatin, ifosfamide, mitomycin C and gemcitabine. Three drug combinations such as vinorelbine, cisplatin and ifosfamide can clearly produce high response rates in patients with good performance status at the time of treatment. The ability of vinorelbine to contribute to disease reduction either alone or in combination with other cytotoxic drugs has made it possible to consider its use in neo-adjuvant therapy, while the synergistic action of vinorelbine with radiotherapy has encouraged the use of sequential or concomitant chemoradiotherapy producing high response rates after completion of both modalities. The possible role of post-operative adjuvant treatment with Vinorelbine either alone or in combination with cisplatin is being assessed in a prospective trial.",
keywords = "Cisplatin non-small-cell lung cancer, Neo- adjuvant, Radiotherapy, Vinorelbine",
author = "Gralla, {Richard J.} and P. Harper and S. Johnson and Delgado, {F. M.}",
year = "1999",
language = "English (US)",
volume = "10",
journal = "Annals of Oncology",
issn = "0923-7534",
publisher = "Oxford University Press",
number = "SUPPL. 5",

}

TY - JOUR

T1 - Vinorelbine (Navelbine®) in the treatment of non-small-cell lung cancer

T2 - Recent developments in combination chemotherapy and radiotherapy

AU - Gralla, Richard J.

AU - Harper, P.

AU - Johnson, S.

AU - Delgado, F. M.

PY - 1999

Y1 - 1999

N2 - The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine and cisplatin as one of the standard treatments for inoperable NSCLC. Alternative partners to cisplatin have been evaluated in combination therapy with vinorelbine with promising results emerging from combinations with carboplatin, ifosfamide, mitomycin C and gemcitabine. Three drug combinations such as vinorelbine, cisplatin and ifosfamide can clearly produce high response rates in patients with good performance status at the time of treatment. The ability of vinorelbine to contribute to disease reduction either alone or in combination with other cytotoxic drugs has made it possible to consider its use in neo-adjuvant therapy, while the synergistic action of vinorelbine with radiotherapy has encouraged the use of sequential or concomitant chemoradiotherapy producing high response rates after completion of both modalities. The possible role of post-operative adjuvant treatment with Vinorelbine either alone or in combination with cisplatin is being assessed in a prospective trial.

AB - The investigation of the activity of vinorelbine in non-small-cell lung cancer (NSCLC) has continued beyond the initial studies which established its single agent activity and defined the combination of vinorelbine and cisplatin as one of the standard treatments for inoperable NSCLC. Alternative partners to cisplatin have been evaluated in combination therapy with vinorelbine with promising results emerging from combinations with carboplatin, ifosfamide, mitomycin C and gemcitabine. Three drug combinations such as vinorelbine, cisplatin and ifosfamide can clearly produce high response rates in patients with good performance status at the time of treatment. The ability of vinorelbine to contribute to disease reduction either alone or in combination with other cytotoxic drugs has made it possible to consider its use in neo-adjuvant therapy, while the synergistic action of vinorelbine with radiotherapy has encouraged the use of sequential or concomitant chemoradiotherapy producing high response rates after completion of both modalities. The possible role of post-operative adjuvant treatment with Vinorelbine either alone or in combination with cisplatin is being assessed in a prospective trial.

KW - Cisplatin non-small-cell lung cancer

KW - Neo- adjuvant

KW - Radiotherapy

KW - Vinorelbine

UR - http://www.scopus.com/inward/record.url?scp=0032692746&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032692746&partnerID=8YFLogxK

M3 - Article

C2 - 10582139

AN - SCOPUS:0032692746

VL - 10

JO - Annals of Oncology

JF - Annals of Oncology

SN - 0923-7534

IS - SUPPL. 5

ER -